Helmut ★★★ Vienna, Austria, 20191016 15:14 (1854 d 05:45 ago) Posting: # 20690 Views: 14,500 

Dear all, sometimes I see reports with a strange pattern of missing periods, e.g., subjects without the 1^{st} period, subjects with only the 1^{st} and the 4^{th}, etc. Since I have only the statistical part of the report, I have no clue what was going on. For the FDA’s RSABE only subjects with complete data (all periods) are used. But this is not the case for the EMA’s ABEL (all subjects with at least one T and R treatment for the calculation of the CI, all subjects with two R treatments for the calculation of CV_{wR}). I would say:
I saw even cases where a subject in sequence TRTR had data only of periods 1 & 3. Useless. Another case: 44 subjects had two administrations of T and R. However, 15 had two administrations of T and 39 two administrations of R. Chance – or what? — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
ElMaestro ★★★ Denmark, 20191016 17:10 (1854 d 03:49 ago) @ Helmut Posting: # 20693 Views: 12,205 

Hi Hötzi, ❝ I would say:
Not a definitive answer, but at some CROs they have SOPs in place to the effect of allowing subjects to come back after they have skipped a period , or fractions of one. This, I think, relates originally to FDA's data driven policies. A subject can walkout on her/his own initiative without even stating a reason, that's how GCP works. There is no clause saying she/he can't come back. I know, this is messy, but that's the way it is in some clinics. The alternative may be worse, depending on how you look at it: If a subject misses an ambulatory pksample ("I forgot", "I sat stuck in a traffic jam", "My parrot suffered an anxiety attack", "Don't you fucking ask me what I did yesterday, it's none of your business", "I had to watch Conchita Wurst win the Grand Prix" etc.) should she/he then be considered completely out? — Pass or fail! ElMaestro 
Helmut ★★★ Vienna, Austria, 20191017 12:22 (1853 d 08:37 ago) @ ElMaestro Posting: # 20700 Views: 12,009 

Hi ElMaestro, ❝ This, I think, relates originally to FDA's data driven policies. A subject can walkout on her/his own initiative without even stating a reason, that's how GCP works. There is no clause saying she/he can't come back. ❝ I know, this is messy, but that's the way it is in some clinics. I see. Since the data are useless for the FDA’s referencescaling maybe this was a trickshot of the CRO to milk the sponsor. ❝ The alternative may be worse, depending on how you look at it: If a subject misses an ambulatory pksample […] should she/he then be considered completely out? I like your examples! That’s an area of improvement which requires a good amount of intellectual horsepower. Not easy but the idea is to come up with rules specifying how many missings (and where) in the profile will likely lead to unreliable estimates of a given PK metric. — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
M.tareq ☆ 20200409 17:24 (1678 d 03:35 ago) @ Helmut Posting: # 21325 Views: 10,191 

❝ I like your examples! That’s an area of improvement which requires a good amount of intellectual horsepower. Not easy but the idea is to come up with rules specifying how many missings (and where) in the profile will likely lead to unreliable estimates of a given PK metric. In one of your lectures, you mentioned comparing the two profile as is, meaning AUC_{012} to AUC_{072}, but won't be comparing orange vs apples, mean, if, for example the first AUC_{012} (drug A) covers 50% of the profile while the comparator AUC_{072} (drug B) covers 80%, is this a biased comparison? Other method that was mentioned in the forum/lectures more often; is is doing loglinear regression using the terminal part of the profile with missing points and perform extrapolation to estimate such points, but no mentioned of such methods in any of the guidelines my question is: if comparing AUC_{0t} as is (missing points are ignored) without doing the extrapolation and the BE criteria not met but when doing the extrapolation the BE is achieved, how such predicament will be handled by the assessor and/or CRO ? Mahmoud 
Helmut ★★★ Vienna, Austria, 20200409 18:15 (1678 d 02:44 ago) @ M.tareq Posting: # 21327 Views: 9,991 

Hi Mahmoud, ❝ In one of your lectures, you mentioned comparing the two profile as is, meaning AUC_{012} to AUC_{072}, … Well, that’s extreme. Did I really give such an example somewhere? ❝ … but won't be comparing orange vs apples, mean, if, for example the first AUC_{012} (drug A) covers 50% of the profile while the comparator AUC_{072} (drug B) covers 80%, is this a biased comparison? If we talk about immediate release and the earliest common last sampling time point is at ≤2×t_{max}, no. In such a case absorption is essentially complete and the later time points are not informative at all (they describe only elimination, which is a property of the drug – not the formulations). See Fisher et al. 2016^{1} My personal PKguru Les Benet applied it in one of his studies.^{2} ❝ Other method that was mentioned in the forum/lectures more often; is is doing loglinear regression using the terminal part of the profile with missing points and perform extrapolation to estimate such points, but no mentioned of such methods in any of the guidelines Up to you. As long as you describe the procedure unambiguously in the SAP (which has to be accepted by the agency), fine. That’s my standard procedure for ages. No guideline is that specific. ❝ my question is: if comparing AUC_{0t} as is (missing points are ignored) without doing the extrapolation and the BE criteria not met but when doing the extrapolation the BE is achieved, how such predicament will be handled by the assessor and/or CRO ? Well, you should evaluate the study according to the SAP, right? Given, “at home” you can perform anything. If any other method will come to a conclusion different from the planned one and you present it as supportive information, I expect that any agency will essential say: “Thank you very much, interesting indeed. We play it safe and reject the study.” Let’s reverse the idea. We know that a comparison of AUC_{0–t} is biased if the last measurable sampling time point in a certain subject differs for T and R (even if true bioavailabilities are identical). That’s not rocket science but basic PK. You followed the GL and the study passes. Would you really try another method afterwards (which fails) and show the result to the agency? I doubt it.
— Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
M.tareq ☆ 20200409 18:54 (1678 d 02:05 ago) @ Helmut Posting: # 21328 Views: 10,015 

❝ Well, that’s extreme. Did I really give such an example somewhere? Think it was mentioned here: https://bebac.at/lectures/Leuven2013WS1.pdf#page=37 not specifically AUC_{012} vs AUC_{072}, but AUC with with different time points ❝ Up to you. As long as you describe the procedure unambiguously in the SAP (which has to be accepted by the agency), fine. That’s my standard procedure for ages. No guideline is that specific. Guess CRO should have accounted for COVID19 impact on missingness of ambulatory samples But as always thanks alot for your prompt reply! Stay safe and well! Mahmoud 
d_labes ★★★ Berlin, Germany, 20191017 19:22 (1853 d 01:37 ago) @ Helmut Posting: # 20701 Views: 11,957 

Dear Helmut! ❝ sometimes I see reports with a strange pattern of missing periods, e.g., subjects without the 1^{st} period, subjects with only the 1^{st} and the 4^{th}, etc. ... ❝ Did you see cases like this? And if yes, do you know why? Yes, I saw such cases in times I was active. F.i. a subject refuses consent after the 2nd period but came back due to invention of the investigator (by phone) for the 4th period (arguments: "you will not get payed if you refuse, only if you come back" or "Please, please be so kind to continue because otherwise we have not the scientific success we expected" and so on. See ElMaestros post for other examples.) What to do with such data? DUNO exactly. You yourself have described what to do for EMA ABEL or FDA RSABE. Any case left? — Regards, Detlew 
ElMaestro ★★★ Denmark, 20191017 22:17 (1852 d 22:42 ago) @ d_labes Posting: # 20702 Views: 11,942 

Hi d_labes, ❝ "you will not get payed if you refuse, only if you come back" ❝ "Please, please be so kind to continue because otherwise we have not the scientific success we expected" §4.8.3: Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to participate or to continue to participate in a trial. — Pass or fail! ElMaestro 
d_labes ★★★ Berlin, Germany, 20191018 13:48 (1852 d 07:11 ago) @ ElMaestro Posting: # 20703 Views: 11,944 

Dear ElMaestro, ❝ ... ❝ §4.8.3: Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to participate or to continue to participate in a trial. Was of course not an unduly influence. Only a friendly talk by phone to obtain some informations about the reasons and circumstances of refusing the continuation. — Regards, Detlew 
Helmut ★★★ Vienna, Austria, 20191019 16:30 (1851 d 04:29 ago) @ d_labes Posting: # 20706 Views: 11,918 

Dear Detlew, ❝ You yourself have described what to do for EMA ABEL or FDA RSABE. Yep. ❝ Any case left? Nope. I was just wondering what could be the cause of such results. — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Astea ★★ Russia, 20191020 16:46 (1850 d 04:12 ago) @ Helmut Posting: # 20709 Views: 11,883 

Dear smart people! I've got two questions on this topic, that could be logically combined into the one philosophical: should we try to keep as much data as possible for the analysis? 1). How would you advice to deal with subjects, who have only one (2,3..) points over LLOQ in one of the periods? According to EMA it is possible to exclude subjects with AUC of reference product less than 5% of geometric mean AUC. Should we exclude all the data of such a subject or can we remain data from other periods? Example: acetylcalycic acid (ASA) in entericcoated form has a widerange T_{max} in about 2 to 7 hours with extremely rapid conversion to salycic acid. So PK profiles look like "zerozerovertical linezerozero"... For catching it one has to plan a great number of sample points and use appropriate stabilization procedure. Even in these case there could be the uppermentioned problems. 2). What was the real reason for FDA to develop an algorithm for NTIDs with only complete data? As Helmut mentioned in the post, theoretically it is possible to use all the data even with incomplete data. Why then FDA just throw data of subjects with incomplete data to the bin? Is not it unethical? (I can't understand this point) — "Being in minority, even a minority of one, did not make you mad" 
Helmut ★★★ Vienna, Austria, 20191020 17:23 (1850 d 03:36 ago) @ Astea Posting: # 20710 Views: 11,922 

Hi Nastia, ❝ Dear smart people! ❝ should we try to keep as much data as possible for the analysis? In principle yes – as long as the outcome is meaningful. ❝ 1). How would you advice to deal with subjects, who have only one (2,3..) points over LLOQ in one of the periods? […] Tricky – IMHO, case by case (should be laid down in an SOP or the SAP, of course). IIRC, Health Canada had a rule that 1 (one!) concentration is sufficient for C_{max} and 3 (oh dear!) fo AUC. Gone with the wind. THX, HC. ❝ 2). What was the real reason for FDA to develop an algorithm for NTIDs with only complete data? No idea. The same is applicable to all RSABEmethods of the FDA. ❝ […] theoretically it is possible to use all the data even with incomplete data. Sure. ❝ Why then FDA just throw data of subjects with incomplete data to the bin? Again – no idea. ❝ Is not it unethical? (I can't understand this point) IMHO, it is and we are not alone with this conclusion.* If SABE is applied, subjects with one missing R observation should be eliminated […]. This is unprecedented in our experience in a regulated bioequivalence setting. Traditionally, one does not exclude data unless there is a scientifically or clinically valid reason to do so. However, with the current draft guidance from FDA for progesterone bioequivalence, this appears to be the immediate approach to be applied for SABE.
— Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Astea ★★ Russia, 20191021 03:59 (1849 d 17:00 ago) @ Helmut Posting: # 20711 Views: 11,834 

Dear Helmut and other smart people! ❝ Are you talking to me? ❝ Tricky – IMHO, case by case (should be laid down in an SOP or the SAP, of course). IIRC, Health Canada had a rule that 1 (one!) concentration is sufficient for C_{max} and 3 (oh dear!) fo AUC. Gone with the wind. THX, HC. Suppose we have only one measurable concentration and it is as high as C_{max} of other periods. Even in this case formally we can calculate AUC for linear trapezoidal rule (depending on the rule for BLOQ data of course). And it can be more than 5 percent of geometric mean of other AUC in this period. Leave it or waste it  any choice will be wrong 
Helmut ★★★ Vienna, Austria, 20191021 13:37 (1849 d 07:22 ago) @ Astea Posting: # 20712 Views: 11,940 

Dear Nastia, ❝ Suppose we have only one measurable concentration and it is as high as C_{max} of other periods. Even in this case formally we can calculate AUC for linear trapezoidal rule […]. And it can be more than 5 percent of geometric mean of other AUC in this period. Leave it or waste it  any choice will be wrong Well, that’s why I wrote above ❝ ❝ […] as long as the outcome is meaningful. We have to go out on a limb to call a triangle a “curve”. — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Mahmoud ★ Jordan, 20191106 12:41 (1833 d 07:18 ago) @ Helmut Posting: # 20753 Views: 11,507 

Dear all ===== For missing data in Be studies in certain period if you need to take into account the missing data use proc mixed in SAS with dffm=Kr otherwise use proc glm in SAS, this procedure do not take into account the missing data 
Helmut ★★★ Vienna, Austria, 20191106 13:49 (1833 d 06:10 ago) @ Mahmoud Posting: # 20754 Views: 11,413 

Hi Mahmoud, ❝ if you need to take into account the missing data use proc mixed in SAS with dffm=Kr From a theoretical perspective, maybe. The KenwardRoger approximation recovers more information from the data, higher degrees of freedom and hence, results in a narrower confidence interval than with Satterthwaite’s degrees of freedom. Since the latter is explicitly recommended in the progesterone guidance I have some doubts whether the FDA would accept that. ❝ otherwise use proc glm in SAS, this procedure do not take into account the missing data Sure. — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
PharmCat ★ Russia, 20191106 15:43 (1833 d 04:16 ago) @ Helmut Posting: # 20755 Views: 11,493 

❝ From a theoretical perspective, maybe. The KenwardRoger approximation recovers more information from the data, higher degrees of freedom and hence, results in a narrower confidence interval than with Satterthwaite’s degrees of freedom. Since the latter is explicitely recommended in the progesterone guidance I have some doubts whether the FDA would accept that. I thought that KenwardRoger provide the same DF as Satterthwaite's for onedimension effects, so as CI for coefficient is onedimension hypothesis DF should be the same, as it describes in reference paper, may be SAS make any corrections, I don't know... Is any comparations anywhere? 
Helmut ★★★ Vienna, Austria, 20191108 21:57 (1830 d 22:02 ago) @ PharmCat Posting: # 20771 Views: 11,270 

Hi PharmCat, ❝ I thought that KenwardRoger provide the same DF as Satterthwaite's for onedimension effects, so as CI for coefficient is onedimension hypothesis DF should be the same, as it describes in reference paper, may be SAS make any corrections, I don't know... Try this one:
The EMA’s Method B evaluated by lmer() of package lmerTest . KenwardRoger’s degrees of freedom ≥ Satterthwaite’s.— Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
PharmCat ★ Russia, 20191108 23:08 (1830 d 20:51 ago) @ Helmut Posting: # 20773 Views: 11,421 

❝ The EMA’s Method B evaluated by May be it's specific of realization in lmer. I can't understand what's under the hood I will make test in SAS. 
mittyri ★★ Russia, 20191108 23:59 (1830 d 20:00 ago) @ PharmCat Posting: # 20774 Views: 11,278 

Hi PharmCat, ❝ I thought that KenwardRoger provide the same DF as Satterthwaite's for onedimension effects, so as CI for coefficient is onedimension hypothesis DF should be the same, as it describes in reference paper, may be SAS make any corrections, I don't know... "KR modify the statistic F to improve the small sample properties by approximating the distribution of F by an F_{d,m} distribution, and they also provide a method for calculating the denominator degrees of freedom m. The fundamental idea is to calculate the approximate mean and variance of their statistic and then match moments with an F distribution to obtain the denominator degrees of freedom." from here ❝ Is any comparations anywhere? yes, plenty of. For example here Also citing Kuznetsova et al.: "From our practice, we observed that the p values that the approximation methods provide are generally very close to each other. Schaalje, McBride, and Fellingham (2002) performed a number of simulations in order to investigate the appropriateness of the approximation methods. They discovered that complexity of the covariance structures, sample size and imbalance affect the performance of both approximations. However, these factors affect the Satterthwaite’s method more than the KenwardRoger’s." — Kind regards, Mittyri 
PharmCat ★ Russia, 20191109 01:51 (1830 d 18:08 ago) @ mittyri Posting: # 20775 Views: 11,357 

I look this or here. "Lemma 7.2.1 When l = 1, the Satterthwaite, the KR and the proposed methods give the same estimate of the denominator degrees of freedom" p.98 proof in source. For coefficient estimate l = 1, and thou I thought they should be equal (and the really equal in SAS). But when DDFM=KENWARDROGER is set  variancecovariance matrix of the fixed effects is corrected too and resulting CI would be differ  this I didn’t take it into account. 
Helmut ★★★ Vienna, Austria, 20191109 17:22 (1830 d 02:37 ago) @ mittyri Posting: # 20778 Views: 11,945 

Hi mittyri and all other nerds, a rant from Douglas Bates (maintainer of lme4 ) reproduced in all of its beauty:Users are often surprised and alarmed that the summary of a linear mixed model fit by — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
PharmCat ★ Russia, 20191109 20:11 (1829 d 23:48 ago) @ Helmut Posting: # 20779 Views: 11,205 

❝ Hi mittyri and all other nerds, Hi all again from this part holy war began usually I really love how Douglas writes and this is one more of his explanation. And I fully support this point of view and concept of statistical purity (lme4, MixedModels.jl ets): you have modeling results and then do what you want. Problem is that we have real "degrees of freedom police" I think that more compromised and more conservative is a "contain" DF = N  rank(XZ), but FDA wrote Satterthwaite. 